Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from SGEN

Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer

A bladder cancer treatment combo tied to a quartet of companies — including Seagen — succeeded in a study on Friday, leading SGEN stock to surge.

Investors Business Daily

Should You Buy Into Pfizer (PFE) Today?

Despite a slowdown of Covid-19 vaccine sales in the last reported quarter, biopharmaceutical giant Pfizer (PFE) is positioned to deliver robust growth this year and beyond, thanks to the strength of its in-line products and expected near-term launches and revenue distribution from the recent acquisition. So, let’s find out if…

StockNews.com

Buy, Sell, or Hold: Pfizer Inc. (PFE)

Pfizer (PFE) continues to make significant strides in the pharmaceutical industry, given its recent acquisition and drug approvals. Is the stock a buy, sell, or hold now? Keep reading to find out….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

2 Robinhood Stocks to Buy and Hold Forever

StockNews.com

The Smartest Stock to Buy for Under $50 Now

Pharma giant Pfizer (PFE) had a successful fiscal year 2022 with record-breaking revenue and earnings. Moreover, its recent acquisition should boost its portfolio and revenue. Given the market volatility, this fundamentally strong stock might be an ideal buy for under $50. Keep reading.

StockNews.com

Seagen Nabs $43 Billion Pfizer Deal; Sanofi Scoops Up Provention Bio

Pfizer will buy Seagen for roughly $43 billion, and Sanofi will buy Provention for $2.9 billion. SGEN stock and PRVB stock soared.

Investors Business Daily

'Here We Go Again': Seagen Soars As Pfizer Reportedly Mulls A Takeover

Pfizer is in early talks to acquire cancer specialist Seagen, according to a report that sent SGEN stock flying on Monday.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Why Seattle Genetics, Alkermes Are Currently Outperforming Their Peers

Seattle Genetics and Alkermes beat fourth-quarter estimates Thursday, pushing Alkermes stock into a brief breakout as SGEN stock soared.

Investors Business Daily

Merck's Rumored $40 Billion Seagen Takeover Hits A Snag On Price

Merck's rumored takeover of cancer-focused biotech Seagen has stalled on price, according to a report Friday that sent SGEN stock tumbling.

Investors Business Daily

Does Merck Finally Have The Fodder It Needs To Buy Seagen?

Seagen lost a royalty battle Friday, but SGEN stock jumped on the potential the rumored Merck acquisition could be looming.

Investors Business Daily

Seagen Tips Its Hand In Bladder Cancer, But Is It Enough To Woo Merck?

Nearly two-thirds of bladder cancer patients responded to a combination from Seagen and Merck, leading SGEN stock to jump Tuesday.

Investors Business Daily

Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Why Merck's Rumored $40 Billion Seagen Buyout Is On Shaky Ground

Merck is unlikely to finalize the rumored takeover of Seagen before its earnings release, and SGEN stock toppled Monday.

Investors Business Daily

Check Out What Whales Are Doing With SGEN

A whale with a lot of money to spend has taken a noticeably bullish stance on Seagen. Looking at options history for Seagen (NASDAQ:SGEN) we detected 10 strange trades.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Merck Reportedly Eyes $40 Billion Seagen Tie-Up; Will The Deal Save Biotech?

Merck is now in advanced talks to buy Seagen for roughly $40 billion, according to reports that sent SGEN stock higher Thursday.

Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,400 Today

Seagen (NASDAQ:SGEN) has outperformed the market over the past 5 years by 18.41% on an annualized basis producing an average annual return of 27.81%. Currently, Seagen has a market capitalization of $32.98 billion.

Benzinga

This Analyst Believes Seagen Is Evaluating Strategic Alternatives

Raymond James initiated coverage on Seagen Inc (NASDAQ:SGEN) at Outperform with a $220 target price. Citing the recent departure of the long-time Seagen CEO, Raymond James thinks that the Board of Directors is likely evaluating strategic alternatives for the company. The relationship with Merck & Company, Inc. (NYSE:MRK) has been long-standing. With Keytruda losing its patent…

Investors Business Daily

Seagen Surges As Merck Takeover Deal Reportedly Accelerating

Merck is reportedly nearing a takeover of cancer biotech Seagen, according to a report Friday that prodded SGEN stock higher.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ

Merck & Co Inc (NYSE:MRK) is pushing forward with a potential deal for Seagen Inc (NASDAQ:SGEN), Wall Street Journal reported, citing people familiar with the matter. The Journal mentioned that the deal could be one of the largest takeovers of the year. The Wall Street Journal reported last week that Merck was in talks to…

Benzinga

Where Seagen Stands With Analysts

Analysts have provided the following ratings for Seagen (NASDAQ:SGEN) within the last quarter:

Benzinga

SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal - What Investors Need To Know

SVB Securities conducted a pro-forma analysis of the financial impact to Merck & Co Inc (NYSE: MRK) from a potential acquisition of Seagen Inc (NASDAQ: SGEN).

Investors Business Daily

Embattled Biotech Seagen Rockets On Rumors Merck Could Buy It

Merck is reportedly eyeing a takeover of embattled biotech Seagen, according to multiple reports that sent SGEN stock flying Friday.

Benzinga

Merck Shows Takeover Interest In Seagen: WSJ

Merck & Co Inc (NYSE:MRK) is reportedly mulling buying cancer-focused biotech Seagen Inc (NASDAQ:SGEN), Wall Street Journal reported citing people familiar with the matter. If the deal happens, it would be significant, given Seagen's market value of roughly $28 billion. According to the report, some people said other unnamed suitors are also eying Seagen, a…

Benzinga

$100 Invested In Seagen 20 Years Ago Would Be Worth This Much Today

Seagen (NASDAQ:SGEN) has outperformed the market over the past 20 years by 12.54% on an annualized basis producing an average annual return of 19.38%. Currently, Seagen has a market capitalization of $26.91 billion.

Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,200 Today

Seagen (NASDAQ:SGEN) has outperformed the market over the past 5 years by 5.77% on an annualized basis producing an average annual return of 17.01%. Currently, Seagen has a market capitalization of $26.17 billion.

1 2

People

Kritika SarmahHer

701 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.